It is odd though, Mercks performance is hollow and should get a haircut soon. They borrow money to buy back shares, suvorexant has issues at higher dosages, generics are hitting Singulair, Januvia is in the past with new competition etc. Amgen is the future. I loaded up big time again over the last few days.
Actually I like buying good companies near the 200 dma as historically they generally bounce to the upside. Nerve wrecking as it is! Last two days we've seen high volume on this selloff which could be a sign of bottoming. AMGN has some good drugs in the pipeline and I see no reason other than profit taking after the recent run-up!